Visit Website →
← Back to blog

Prevent FDA Delays in Lot Release Testing for U.S. QC

September 30, 2026
Prevent FDA Delays in Lot Release Testing for U.S. QC

Lot release testing is the process by which a biologic manufacturer confirms that each production lot meets its approved specifications before distribution, and, for certain products, submits results to the FDA for review or confirmatory testing. Requirements are product-specific and set at the time of licensure. Manufacturers must justify their chosen assays against approved specifications, and submissions typically move through the agency's Electronic Submissions Gateway with a signed e-LRP letter attached.

TL;DR:

  • Most lot release protocols are reviewed within 30 business days of submission, but delays occur with incomplete or poorly documented submissions.
  • Key assays include identity and purity tests using HPLC and mass spectrometry, as well as microbial limits and potency assays tailored to the product’s mechanism.
  • Labs must validate assays according to ICH Q2(R1), participate in proficiency testing, and maintain documented quality systems to ensure data trustworthiness.
  • Out-of-specification results require orthogonal confirmation, thorough investigation, and documentation before releasing or rejecting a lot.
  • Building risk-based, product-specific test panels anchored in data and early validation improves reliability and regulatory compliance.
USAPeptide
Strengthen Your Peptide Quality Review
USAPeptide provides research-grade compounds, molecular profiles, and Certificates of Analysis to support documented laboratory quality checks.
Explore USAPeptide resources

Table of Contents

Overview: why lot release exists and who is responsible

Lot release functions as an ongoing quality check rather than a one-time approval hurdle. It gives regulators a real-time window into manufacturing consistency long after a product reaches the market, catching drift that a single approval decision could never anticipate.

Not every lot triggers independent laboratory testing. In many cases, the FDA reviews the manufacturer's protocol and summary results without repeating the testing itself, reserving confirmatory analysis for products or situations that warrant closer scrutiny.

Several parties share responsibility for the system:

  • The manufacturer performs the release testing, compiles the protocol, and submits it for review.
  • The Product Release Branch within CBER manages incoming submissions, sample custody, and reviewer assignment.
  • National control laboratories, where involved, conduct independent confirmatory testing on a defined subset of lots.

Regulatory framework and key standards you must reference

The legal foundation for lot release sits in Subpart A of 21 C.F.R. Part 610, which grants FDA the authority to require protocol submission and, when warranted, confirmatory testing before distribution. FDA's lot release page describes this as a mechanism for verifying quality through protocol review rather than a fixed inspection schedule.

Lot release protocols reach a decision within 30 business days of a complete submission, according to FDA's stated timeline, though this is a goal rather than a legal requirement, and incomplete submissions routinely push it back.

Three reference points matter most for building a defensible testing program:

  • ICH Q6B ties acceptance criteria to development data rather than arbitrary limits.
  • SOPPs and FDA guidance on electronic submissions define the mechanics of getting a protocol into agency hands correctly.
  • WHO guidance offers a parallel framework for products reviewed under other regulatory systems.

Common assays and methods used for lot release testing

A typical release panel blends physicochemical, microbiological, and biological testing, with the exact mix dictated by the product's structure and intended use.

Identity and purity testing usually relies on HPLC, mass spectrometry, and particulate matter analysis to confirm the molecule is what it claims to be and free of unacceptable contaminants. Sterility, endotoxin testing (traditionally LAL-based, though alternative methods are gaining ground), microbial limits, and bioburden testing address the risk of contamination reaching a patient. For biologics with a functional mechanism, potency assays carry particular weight: cell-based assays, ADCC or ADCP assays for antibody-dependent mechanisms relevant to complex biologics and antibody-drug conjugates, and a choice between in vitro and in vivo formats depending on what the mechanism actually requires.

  • Identity and purity: HPLC, mass spectrometry, particulate matter analysis.
  • Sterility and contamination control: sterility testing, endotoxin assays, microbial limits, bioburden.
  • Function: cell-based or ADCC and ADCP potency assays tied to the product's mechanism.

No single assay tells the whole story. Orthogonal methods and well-characterized reference standards are what let a lab defend a release decision when a result sits close to a specification limit.

Pro Tip: Keep at least one orthogonal method validated and ready for any assay prone to borderline results, so a confirmatory run does not require an emergency validation project.

How tests are selected: building a risk-based, product-specific test panel

Selecting a release panel is an exercise in justification, not just measurement. ICH Q6B ties every acceptance criterion to the preclinical, clinical, manufacturing, and stability data that support it, meaning a limit cannot simply be borrowed from a similar product.

  1. Anchor each acceptance criterion to the specific data set that justifies it: clinical exposure data for potency, process validation data for impurities, stability data for degradation-related limits.
  2. Set release limits tighter than shelf-life limits when the data show a product's attributes shift over time, and document the rationale for the gap.
  3. Evaluate in-process controls and real-time release testing as substitutes for certain end-product tests, where the manufacturing process and validation history support that substitution.

Lot release protocol and submission logistics (ESG, e-LRP, sample custody)

Submissions to CBER move through the Electronic Submissions Gateway, using either the WebTrader interface or an AS2 connection, as described in FDA's guidance on electronic lot release protocols.

Samples themselves travel separately from the electronic protocol, addressed to the Sample Custodian, and manufacturers running concurrent testing at the time of submission should include a concurrent testing letter so reviewers know what to expect and when.

  • Confirm ESG credentials and connection type well before a submission deadline.
  • Match filenames and the e-LRP signature letter exactly to the format specified in the guidance.
  • Coordinate courier timing so physical samples arrive close to when the electronic protocol is received.
  • Include a concurrent testing letter whenever testing is still underway at submission time.

Laboratory quality systems, proficiency testing, and accreditation expectations

Regulators trust lot release data because the laboratory generating it operates under a documented quality system, not because a single test result looks clean. ISO/IEC 17025 accreditation and method validation aligned with ICH Q2(R1) parameters (accuracy, precision, specificity, and related criteria) are the baseline expectations for any lab producing release data.

  • Validate each quantitative and qualitative assay against ICH Q2(R1) parameters before it enters routine use.
  • Participate in external proficiency testing or EQA programs to demonstrate ongoing competence, an expectation reflected in WHO quality management guidance.
  • Track internal QC samples, calibration verification, and control trends over time rather than reviewing them lot by lot in isolation.
  • Maintain SOPs and CAPA records that trace every deviation back to its root cause.

Pro Tip: Review proficiency testing results as a trend line across cycles, not as a single pass or fail, since a lab's competence shows up in consistency over time.

Handling out-of-specification results, retest policy, and release decisions

An OOS result should trigger a defined sequence, not an ad hoc scramble.

  1. Hold the lot and preserve the original sample before any further testing begins.
  2. Run an orthogonal confirmatory method rather than simply repeating the original assay.
  3. Convene a QA and technical review to assess the result against method history and known assignable causes.
  4. Document the investigation and any corrective action in a CAPA record tied to the specific lot.
  5. Notify or consult the agency when the result affects a lot already under regulatory review, and keep the lot held until that review concludes.

Practical checklist and tools for lot documentation: how USAPeptide resources can help

Documentation quality often determines how smoothly a release decision withstands review. A practical checklist before final sign-off should confirm the following:

  • Certificate of Analysis authenticity, including consistency between reported and expected test methods.
  • HPLC purity evidence that matches the stated specification and testing date.
  • Traceability of reference materials and standards used in the assays.
  • Stability notes and batch identifiers that connect the lot to its supporting data.

USAPeptide's COA grading tool helps research teams assess whether a Certificate of Analysis carries the hallmarks of legitimate testing, while the platform's peptide database and its COA checklist resource support internal documentation review. These tools assist with organizing and verifying paperwork. They do not replace validated assays, formal method validation, or the regulatory submission process itself.

Interpretation of lot release test results and decision-making criteria

A release decision is rarely a single yes or no answer read off a specification sheet. It requires weighing each result against its acceptance criterion while accounting for assay variability, historical trend data, and the clinical relevance of the attribute being measured.

A result that falls within specification but sits near a boundary deserves scrutiny even when it technically passes, particularly for potency assays where a small shift can reflect a real change in manufacturing consistency rather than assay noise. Reviewers typically look at three things together: the individual result, how it compares to the lot's own in-process data, and how it compares to the product's historical release trend. A value that is unusual relative to trend, even if within specification, often prompts a closer look before sign-off.

Orthogonal data plays a similar role. When two independent methods point to the same conclusion, confidence in the release decision goes up considerably. When they diverge, the divergence itself becomes the finding that needs resolution before the lot moves forward.

Stability-indicating assays add another layer, since a result interpreted without reference to the product's known degradation pathway can mask a real quality problem. ICH Q6B explicitly frames specifications as tools for confirming that a lot will remain within acceptable limits through its labeled shelf life, not just at the moment of release. Final sign-off, in practice, is the point where all of this evidence, the raw result, the trend context, the orthogonal confirmation, and the stability linkage, converges into a documented decision that someone outside the lab can review and understand.

Evidence converging on lot release decision

Common challenges and troubleshooting in lot release testing

Assay variability is the most persistent challenge in lot release work. Potency assays in particular, especially cell-based ones, can show run-to-run variation that has nothing to do with product quality and everything to do with cell health, reagent lots, or operator technique. Building assay robustness into the validation stage, rather than discovering it during routine testing, avoids a large share of downstream disputes.

Reference standard drift is a related problem. A reference standard that shifts slightly over time can make an otherwise stable product appear to be degrading, or the reverse. Regular requalification of reference materials against a primary standard catches this before it becomes a release-blocking issue.

Submission logistics create a different category of friction. Filename errors, missing e-LRP signature letters, and absent concurrent testing letters are avoidable causes of delay documented in FDA's electronic submission guidance, yet they remain common. A pre-submission checklist that someone other than the preparer reviews catches most of these before they reach the agency.

Finally, evolving expectations around real-time release testing and in-process controls create genuine ambiguity about when a substitution for end-product testing is defensible. Manufacturers who invest early in the validation data needed to support these alternatives are better positioned when the agency asks for justification, while those who treat it as a future project often find themselves defending outdated testing plans.

Common challenges and troubleshooting in lot release testing — overview diagram

Regulatory testing is drifting toward targeted, risk-based confirmatory testing rather than blanket retesting, with electronic submission now the default rather than the exception. Teams that treat their testing plan as fixed at approval, rather than revisited as surveillance data accumulates, tend to be caught off guard when expectations shift. Build proficiency testing and orthogonal methods into routine practice now, and keep a channel open with the Product Release Branch before problems appear.

— USAPeptide Team

USAPeptide.info resources for COA grading and lot paperwork

Preparing lot documentation is easier with the right reference tools on hand. There are resources offering a COA grading tool to assess Certificate of Analysis legitimacy, a peptide database with detailed molecular profiles, and a COA checklist article that walks through what a defensible certificate should include.

USAPeptide

  • Use the COA grading tool to flag inconsistencies in a supplier's Certificate of Analysis before it enters your lot file.
  • Reference the peptide database for molecular profiles and mechanism details relevant to identity confirmation.
  • Review the COA checklist for a structured approach to lot paperwork.

These resources support documentation and internal review. They are not a substitute for validated assays or formal regulatory filings. Visit Usapeptide to explore the full set of reference tools.

Sources

Keep these on hand when preparing a protocol or defending a testing plan:

FAQ

What is the purpose of pharmaceutical release testing?

Release testing confirms that a specific manufactured lot meets its approved quality specifications before it reaches patients or researchers. It also gives regulators, through protocol review and occasional confirmatory testing, an ongoing check on manufacturing consistency described on FDA's lot release page.

How long does FDA lot release review typically take?

FDA aims to complete review within 30 business days of a complete submission, though this is a goal rather than a fixed legal deadline. Incomplete protocols or requests for clarification commonly extend that timeline.

What happens when a lot release test result is out of specification?

The lot is held and the original sample preserved while the lab runs an orthogonal confirmatory test and convenes a technical review. If the result affects a lot under active regulatory review, the lot stays held pending that review's outcome.

Are lot release specifications the same as shelf-life specifications?

Not necessarily. ICH Q6B allows release limits to be tighter than shelf-life limits when stability data justify the difference, since a product's attributes can shift over its labeled shelf life.

What laboratory credentials support a defensible lot release testing program?

ISO/IEC 17025 accreditation and method validation aligned with ICH Q2(R1) parameters form the baseline expectation, supported by regular participation in external proficiency testing as referenced in WHO quality management guidance.